medisynt offers three highly effective radionuclides—Terbium-161 (Tb-161), Lutetium-177 (Lu-177), and Actinium-225 (Ac-225)—which are used in targeted molecular radiotherapy for the treatment of various cancers.
These radionuclides are distinguished by their ability to precisely destroy tumor cells while largely sparing surrounding healthy tissue. In addition, medisynt plans to expand its portfolio in the near future with further innovative radionuclides to meet the growing demands of personalized cancer therapy.
